Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years

Medidata has announced an extension of its 15-year relationship with the National Cancer Institute (NCI), part of the National Institutes of Health. This renewed commitment, spanning an additional five years, consolidates their joint efforts and underscores their dedication to advancing cancer research.

Since the inception of their partnership in 2008, Medidata and the NCI have collaborated across thousands of clinical trials with the joint mission of pioneering the development of promising treatments of cancer.

“Medidata’s long-standing partnership with the NCI represents our unwavering commitment to supporting critical oncology research,” says Joseph Schmidt, executive vice president, customer success, services, and support, Medidata in a press release. “It is gratifying that 90% of all oncology approvals last year in the US were developed using Medidata software, and we hope to make an even bigger impact alongside the NCI over the next few years in the fight against cancer.”

By standardizing processes and enhancing data collection, the Medidata platform supports accelerated study timelines with the goal of bringing innovative and transformative therapies to patients sooner.

The company’s combination of expertise and clinical trial technologies extends its support to public sector research organizations, encompassing over 3,000 academic clinical trials, 223,000 sites, and benefiting 948,000 patients.

Reference

Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years. (2023, October 4). Business Wire.